Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389

Molecular and Cellular Biology

Volumn 24, Issue 20, 2004, Pages 8884-8894

  Bruins, Wendy ^a   Zwart, Edwin ^a   Attardi, Laura D ^b   Iwakuma, Tomoo ^c   Hoogervorst, Esther M ^a   Beems, Rudolf B ^a   Miranda, Barbara ^d   Van Oostrom, Conny T M ^a   Van Den Berg, Jolanda ^a   Van Den Aardweg, Gerard J ^e   Lozano, Guillermina ^c   Van Steeg, Harry ^a   Jacks, Tyler ^d   De Vries, Annemieke ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; MUTANT PROTEIN; PROTEIN P53; SERINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GAMMA RADIATION; GENE MUTATION; GENE TARGETING; HOMOZYGOSITY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; RADIOSENSITIVITY; SKIN TUMOR; ULTRAVIOLET RADIATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA; CELL CYCLE; CELLS, CULTURED; DOXORUBICIN; FIBROBLASTS; GAMMA RAYS; GENE EXPRESSION REGULATION; HUMANS; MICE; NEOPLASMS, SQUAMOUS CELL; PAPILLOMA; PHENOTYPE; PHOSPHORYLATION; POINT MUTATION; SERINE; SKIN; STEM CELLS; SURVIVAL RATE; THYMUS GLAND; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

ANIMALIA;

EID: 4744373426     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.24.20.8884-8894.2004     Document Type: Article

References (45)

1. Appella, E., and C. W. Anderson. 2000. Signaling to p53: breaking the posttranslational modification code. Pathol. Biol. 48:227-245.
2. Appella, E., and C. W. Anderson. 2001. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268:2764-2772.
3. 1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. Oncogene 23:973-980.
4. Attardi, L. D., and T. Jacks. 1999. The role of p53 in tumour suppression: lessons from mouse models. Cell. Mol. Life Sci. 55:48-63.
5. Attardi, L. D., E. E. Reczek, C. Cosmas, E. G. Demicco, M. E. McCurrach, S. W. Lowe, and T. Jacks. 2000. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev. 14:704-718.
6. Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557.
7. Chao, C., M. Hergenhahn, M. D. Kaeser, Z. Wu, S. Saito, R. Iggo, M. Hollstein, E. Appella, and Y. Xu. 2003. Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J. Biol. Chem. 278:41028-41033.
8. Chao, C., S. Saito, C. W. Anderson, E. Appella, and Y. Xu. 2000. Phosphorylation of murine p53 at ser-18 regulates the p53 responses to DNA damage. Proc. Natl. Acad. Sci. USA 97:11936-11941.
9. Cuddihy, A. R., A. H. Wong, N. W. Tam, S. Li, and A. E. Koromilas. 1999. The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro. Oncogene 18:2690-2702.
10. de Vries, A., E. R. Flores, B. Miranda, H. M. Hsieh, C. T. van Oostrom, J. Sage, and T. Jacks. 2002. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc. Natl. Acad. Sci. USA 99:2948-2953.
11. Donehower, L. A. 1996. The p53-deficient mouse: a model for basic and applied cancer studies. Semin. Cancer Biol. 7:269-278.
12. El Deiry, W. S. 1998. Regulation of p53 downstream genes. Semin. Cancer Biol. 8:345-357.
13. Fiscella, M., N. Zambrano, S. J. Ullrich, T. Unger, D. Lin, B. Cho, W. E. Mercer, C. W. Anderson, and E. Appella. 1994. The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities. Oncogene 9:3249-3257.
14. Funk, W. D., D. T. Pak, R. H. Karas, W. E. Wright, and J. W. Shay. 1992. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12:2866-2871.
15. Hall, S. R., L. E. Campbell, and D. W. Meek. 1996. Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation. Nucleic Acids Res. 24:1119-1126.
16. Hao, M., A. M. Lowy, M. Kapoor, A. Deffie, G. Liu, and G. Lozano. 1996. Mutation of phosphoserine 389 affects p53 function in vivo. J. Biol. Chem. 271:29380-29385.
17. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
18. Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris. 1991. p53 mutations in human cancers. Science 253:49-53.
19. Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25-27.
20. Huang, C., W. Y. Ma, A. Maxiner, Y. Sun, and Z. Dong. 1999. p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J. Biol. Chem. 274:12229-12235.
21. Jacks, T., L. Remington, B. O. Williams, E. M. Schmitt, S. Halachmi, R. T. Bronson, and R. A. Weinberg, 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1-7.
22. Jiang, W., H. N. Ananthaswamy, H. K. Muller, and M. L. Kripke. 1999. p53 protects against skin cancer induction by UV-B radiation. Oncogene 18:4247-4253.
23. Kapoor, M., R. Hamm, W. Yan, Y. Taya, and G. Lozano. 2000. Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene 19:358-364.
24. Kapoor, M., and G. Lozano. 1998. Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc. Natl. Acad. Sci. USA 95:2834-2837.
25. Keller, D., X. Zeng, X. Li, M. Kapoor, M. S. Iordanov, Y. Taya, G. Lozano, B. Magun, and H. Lu. 1999. The p38MAPK inhibitor SB203580 alleviates ultraviolet-induced phosphorylation at serine 389 but not serine 15 and activation of p53. Biochem. Biophys. Res. Commun. 261:464-471.
26. Keller, D. M., X. Zeng, Y. Wang, Q. H. Zhang, M. Kapoor, H. Shu, R. Goodman, G. Lozano, Y. Zhao, and H. Lu. 2001. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol. Cell 7:283-292.
27. Kubbutat, M. H., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303.
28. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
29. Ljungman, M. 2000. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia 2:208-225.
30. Lo, P. K., J. Y. Chen, P. P. Tang, J. Lin, C. H. Lin, L. T. Su, C. H. Wu, T. L. Chen, Y. Yang, and F. F. Wang. 2001. Identification of a mouse thiamine transporter gene as a direct transcriptional target for p53. J. Biol. Chem. 276:37186-37193.
31. Lowe, S. W., E. M. Schmitt, S. W. Smith, B. A. Osborne, and T. Jacks. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849.
32. Lu, H., Y. Taya, M. Ikeda, and A. J. Levine. 1998. Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. Proc. Natl. Acad. Sci. USA 95:6399-6402.
33. Meek, D. W., S. Simon, U. Kikkawa, and W. Eckhart. 1990. The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II. EMBO J. 9:3253-3260.
34. Milne, D. M., R. H. Palmer, and D. W. Meek. 1992. Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53. Nucleic Acids Res. 20:5565-5570.
35. Miyashita, T., S. Krajewski, M. Krajewska, H. G. Wang, H. K. Lin, D. A. Liebermann, B. Hoffman, and J. C. Reed. 1994. Tumor suppressor p53 is a regulator of bcl-2 and box gene expression in vitro and in vivo. Oncogene 9:1799-1805.
36. Miyashita, T., and J. C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human box gene. Cell 80:293-299.
37. Oda, E., R. Ohki, H. Murasawa, J. Nemoto, T. Shibue, T. Yamashita, T. Tokino, T. Taniguchi, and N. Tanaka. 2000. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288:1053-1058.
38. Okamoto, K., and D. Beach. 1994. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 13:4816-4822.
39. Prives, C., and P. A. Hall. 1999. The p53 pathway. J. Pathol. 187:112-126.
40. Sakaguchi, K., H. Sakamoto, D. Xie, J. W. Erickson, M. S. Lewis, C. W. Anderson, and E. Appella. 1997. Effect of phosphorylation on tetramerization of the tumor suppressor protein p53. J. Protein Chem. 16:553-556.
41. Schwenk, F., U. Baron, and K. Rajewsky. 1995. A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. fsNucleic Acids Res. 23:5080-5081.
42. Shieh, S. Y., Y. Taya, and C. Prives. 1999. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J. 18:1815-1823.
43. Sluss, H. K., H. Armata, J. Gallant, and S. N. Jones. 2004. Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol. Cell. Biol. 24:976-984.
44. Venkatachalam, S., Y. P. Shi, S. N. Jones, H. Vogel, A. Bradley, D. Pinkel, and L. A. Donehower. 1998. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 17:4657-4667.
45. Wu, Z., J. Earle, S. Saito, C. W. Anderson, E. Appella, and Y. Xu. 2002. Mutation of mouse p53 Ser23 and the response to DNA damage. Mol. Cell. Biol. 22:2441-2449.